极视角港股IPO：股东转让退出已逾半年为何未办理变更登记？技术服务费激增却未披露研发外包比例

Core Viewpoint - The company, Shandong Jishijiao Technology Co., Ltd. (referred to as "Jishijiao"), is facing significant challenges regarding its IPO application and financial performance, including concerns about its research and development (R&D) expenditures and the legality of its shareholder transactions [1][2][4]. Group 1: IPO and Shareholder Issues - Jishijiao submitted an IPO application to the Hong Kong Stock Exchange on January 20, 2026, with CITIC Securities as the sole sponsor [1]. - In July 2025, Qingdao Tianlu transferred all its shares at a 43.72% discount compared to the D-round financing price, raising questions about the legality of the transaction and whether there is any shareholding proxy [1][2][5]. - The company has not completed the necessary changes to its shareholder registration, which has led to inquiries from the China Securities Regulatory Commission (CSRC) regarding potential violations of regulations [4][30]. Group 2: Financial Performance - Jishijiao has completed 11 rounds of financing, raising a total of 384 million yuan, with a post-investment valuation of 2.31 billion yuan, but recent rounds show stagnation in valuation growth [2][23]. - The company's revenue for the years 2022 to 2025 (up to Q3) was 102 million yuan, 128 million yuan, 257 million yuan, and 136 million yuan, respectively, while net profits were -61 million yuan, -56 million yuan, 9 million yuan, and -36 million yuan, indicating a serious issue of "increasing revenue without increasing profit" [14][36]. - As of September 2025, Jishijiao's unremitted losses reached 135 million yuan, and the company has been in a state of loss for three out of the last four reporting periods [15][37]. Group 3: R&D Expenditures - The company’s R&D expenses totaled 163 million yuan, accounting for only 26.24% of total revenue during the reporting period, raising doubts about the effectiveness of its R&D investments [19][41]. - There has been a significant increase in technical service fees, which rose from 6 million yuan in 2022 to 34 million yuan in the first three quarters of 2025, suggesting a reliance on outsourced R&D services without clear disclosure of the amounts or proportions involved [21][43]. - The decline in personnel costs within R&D from 26 million yuan to 19 million yuan between 2022 and 2024 indicates a potential reduction in the R&D team, further questioning the company's internal capabilities [19][41].